title: Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.
abstract: Imatinib mesylate is a specific inhibitor of BCR-ABL tyrosine kinase, which is now widely used for the treatment of chronic myeloid leukemia (CML) with a high efficacy. Although severe hepatic injury caused by imatinib mesylate is rare, such a side effect may force patients to discontinue taking imatinib mesylate. In the present paper, we report on the case of a 51-year-old woman with CML who experienced hepatic injury with severe hyperbilirubinemia caused by imatinib mesylate. The findings from a liver biopsy specimen and her clinical course suggested the hepatic injury to presumably have been caused by an allergic mechanism. The co-administration of prednisolone was thus tried, and she has been able to continue imatinib mesylate administration without any liver dysfunction and finally was able to obtain a complete cytogenetic response.We therefore recommend that prednisolone should be tried when severe hepatic injury caused by imatinib mesylate is observed, since it might enable such patients to continue imatinib mesylate treatment and thereby improve the prognosis in such cases.
authors.affiliation: Third Department of Internal Medicine, Asahikawa Medical College, Japan. ikuta@asahikawa-med.ac.jp
authors.forename: Katsuya
authors.initials: K
authors.lastname: Ikuta
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Torimoto
authors.forename: Junko
authors.initials: J
authors.lastname: Jimbo
authors.forename: Junki
authors.initials: J
authors.lastname: Inamura
authors.forename: Motohiro
authors.initials: M
authors.lastname: Shindo
authors.forename: Kazuya
authors.initials: K
authors.lastname: Sato
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Tokusashi
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Miyokawa
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kohgo
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D001706:Biopsy; D056486:Chemical and Drug Induced Liver Injury; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008099:Liver / Q000187:drug effects / Q000473:pathology*; D008107:Liver Diseases / Q000188:drug therapy; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D011239:Prednisolone / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011239:Prednisolone; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl